{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T16:57:10Z","timestamp":1781369830122,"version":"3.54.1"},"reference-count":34,"publisher":"Oceanside Publications Inc.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Parental concerns about the adverse effects of asthma medications can lead to nonadherence and uncontrolled asthma in children. Ciclesonide (CIC) is a prodrug, with low oropharyngeal deposition and bioavailability that may minimize the risk of local and systemic\n adverse effects. CIC is U.S. Food and Drug Administration approved for asthma in children ages \u2265 12 years.  <jats:bold>Objective:<\/jats:bold> To summarize safety results from the 13 phase II or III randomized controlled trials conducted in children with asthma during CIC clinical development.\n  <jats:bold>Methods:<\/jats:bold> Four 12- to 24-week trials compared the safety of once-daily CIC 40, 80, or 160 \u00b5g\/day with placebo; four 12-week trials compared the safety of CIC 80 or 160 \u00b5g\/day with either fluticasone or budesonide; one 12-month trial compared the long-term safety\n of CIC 40, 80, or 160 \u00b5g\/day with fluticasone; one 12-month trial compared growth velocity of CIC 40 or 160 \u00b5g\/day with placebo; and three cross-over trials compared short-term growth velocity and hypothalamic-pituitary-adrenal (HPA) axis effects of CIC 40, 80, or 160 \u00b5g\/day\n with placebo or fluticasone.  <jats:bold>Results:<\/jats:bold> In all, 4399 children were treated with CIC. The incidence of treatment-emergent adverse events (AE) was similar among the CIC doses and between CIC and placebo in short-term studies and between CIC and fluticasone in the long-term\n safety study. No CIC-related serious AEs were reported in any study. The incidence of treatment-related oral candidiasis was low and similar between CIC (\u22640.5%) and placebo (\u22640.7%) or active controls (\u22640.5%) in the short-term studies. There was no clinically relevant HPA axis suppression\n or reduction in growth velocity associated with CIC.  <jats:bold>Conclusion:<\/jats:bold> Data from 13 studies demonstrate that CIC is associated with low rates of oropharyngeal AEs, with no indication of clinically relevant systemic effects in children with asthma. The favorable safety profile\n and demonstrated improvements in asthma control make CIC an ideal inhaled corticosteroid for the treatment of asthma in children.<\/jats:p>","DOI":"10.2500\/aap.2021.42.210085","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T20:07:14Z","timestamp":1638821234000},"page":"471-480","source":"Crossref","is-referenced-by-count":3,"title":["Safety of ciclesonide in children with asthma: A review of randomized controlled trials"],"prefix":"10.2500","volume":"42","author":[{"given":"Michael","family":"Blaiss","sequence":"first","affiliation":[{"name":"From the Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Berger","sequence":"additional","affiliation":[{"name":"Allergy and Asthma Associates of Southern California, Mission Viejo, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Chipps","sequence":"additional","affiliation":[{"name":"Capital Allergy and Respiratory Disease Center, Sacramento, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Hernandez-Trujillo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Herbert Wertheim School of Medicine, Florida International University, Miami, Florida;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanda","family":"Phipatanakul","sequence":"additional","affiliation":[{"name":"Division of Immunology and Allergy, Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Steward","sequence":"additional","affiliation":[{"name":"Covis Pharma B.V., Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","article-title":"2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group"},{"key":"B2","article-title":"Global Initiative for Asthma"},{"key":"B3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1398-9995.2006.01090.x","article-title":"Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma","volume":"61","author":"Buhl","year":"2006","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.rmed.2005.11.020","article-title":"Systemic side effects of inhaled corticosteroids in patients with asthma","volume":"100","author":"Dahl","year":"2006","journal-title":"Respir Med"},{"key":"B5","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1177\/0091270007299763","article-title":"Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide","volume":"47","author":"Derendorf","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/0091270004271094","article-title":"Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma","volume":"45","author":"Richter","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00228-005-0910-0","article-title":"Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects","volume":"61","author":"Nave","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00003088-200443070-00004","article-title":"Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects","volume":"43","author":"Nave","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"B9","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.xphs.2016.05.004","article-title":"Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids","volume":"105","author":"Mukker","year":"2016","journal-title":"J Pharm Sci"},{"key":"B10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jpeds.2005.10.028","article-title":"Once-daily ciclesonide in children: efficacy and safety in asthma","volume":"148","author":"Gelfand","year":"2006","journal-title":"J Pediatr"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.rmed.2010.06.012","article-title":"Efficacy and safety of three ciclesonide doses vs placebo in children with asthma: the RAINBOW study","volume":"104","author":"Pedersen","year":"2010","journal-title":"Respir Med"},{"key":"B12","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ppul.21074","article-title":"Beliefs and barriers to medication use in parents of Latino children with asthma","volume":"44","author":"McQuaid","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1399-3038.2011.01150.x","article-title":"Uncontrolled asthma at age 8: the importance of parental perception towards medication","volume":"22","author":"Koster","year":"2011","journal-title":"Pediatr Allergy Immunol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.rmed.2011.07.017","article-title":"Ciclesonide in wheezy preschool children with a positive asthma predictive index or atopy","volume":"105","author":"Brand","year":"2011","journal-title":"Respir Med"},{"key":"B15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.pupt.2008.12.013","article-title":"Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma","volume":"22","author":"Pedersen","year":"2009","journal-title":"Pulm Pharmacol Ther"},{"key":"B16","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/ppul.20474","article-title":"A comparative study of inhaled ciclesonide 160 microg\/day and fluticasone propionate 176 microg\/day in children with asthma","volume":"41","author":"Pedersen","year":"2006","journal-title":"Pediatr Pulmonol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1399-3038.2007.00538.x","article-title":"Comparison of the efficacy and safety of ciclesonide 160 microg once daily vs. budesonide 400 microg once daily in children with asthma","volume":"18","author":"von Berg","year":"2007","journal-title":"Pediatr Allergy Immunol"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.2500\/aap.2021.42.210062","article-title":"Review of efficacy of ciclesonide for the treatment of asthma in children","author":"Blaiss","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1542\/peds.2006-2206","article-title":"Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma","volume":"121","author":"Skoner","year":"2008","journal-title":"Pediatrics"},{"key":"B20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2005.01.066","article-title":"Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide","volume":"115","author":"Agertoft","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"pt 1","key":"B21","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1111\/j.1399-3038.2009.00879.x","article-title":"Lower-leg growth rates in children with asthma during treatment with ciclesonide and fluticasone propionate","volume":"21","author":"Agertoft","year":"2010","journal-title":"Pediatr Allergy Immunol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2500\/aap.2009.30.3224","article-title":"The safety profile of ciclesonide in the treatment of persistent asthma","volume":"30","author":"Craig","year":"2009","journal-title":"Allergy Asthma Proc"},{"key":"B23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1834-7819.2010.01226.x","article-title":"Asthma and oral health: a review","volume":"55","author":"Thomas","year":"2010","journal-title":"Aust Dent J"},{"key":"B24","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.mayocp.2012.06.022","article-title":"Practical considerations for dysphonia caused by inhaled corticosteroids","volume":"87","author":"Galv\u00e1n","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"B25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/jam.2006.19.117","article-title":"Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers","volume":"19","author":"Leach","year":"2006","journal-title":"J Aerosol Med"},{"key":"B26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.rmed.2005.09.027","article-title":"High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma","volume":"100","author":"Newman","year":"2006","journal-title":"Respir Med"},{"key":"B27","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.rmed.2010.05.021","article-title":"Difference between patient-reported side effects of ciclesonide versus fluticasone propionate","volume":"104","author":"van der Molen","year":"2010","journal-title":"Respir Med"},{"key":"B28","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.rmed.2007.03.001","article-title":"A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma","volume":"101","author":"Boulet","year":"2007","journal-title":"Respir Med"},{"key":"B29","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.pupt.2007.05.002","article-title":"Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma","volume":"21","author":"Bateman","year":"2008","journal-title":"Pulm Pharmacol Ther"},{"key":"B30","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.rmed.2007.05.006","article-title":"Randomized comparison of the efficacy and safety of ciclesonide and budesonide in adolescents with severe asthma","volume":"101","author":"Vermeulen","year":"2007","journal-title":"Respir Med"},{"key":"B31","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.rmed.2005.11.030","article-title":"Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma","volume":"100","author":"Boulet","year":"2006","journal-title":"Respir Med"},{"key":"B32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.clinthera.2006.06.014","article-title":"A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma","volume":"28","author":"Hansel","year":"2006","journal-title":"Clin Ther"},{"key":"B33","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1203229","article-title":"Effect of inhaled glucocorticoids in childhood on adult height","volume":"367","author":"Kelly","year":"2012","journal-title":"N Engl J Med."},{"key":"B34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/pai.12558","article-title":"Influence of inhaled corticosteroids on pubertal growth and final height in asthmatic children","volume":"27","author":"De Leonibus","year":"2016","journal-title":"Pediatr Allergy Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2021\/00000042\/00000006\/art00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T04:50:27Z","timestamp":1640235027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2021.42.210085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11,1]]}},"alternative-id":["1088-5412(20211101)42:6L.471;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2021.42.210085","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}